Cedarbaum J M, Toy L H, Green-Parsons A
Department of Neurology and Neuroscience, Cornell University Medical College, Burke Rehabilitation Center, White Plains, New York.
Clin Neuropharmacol. 1991 Jun;14(3):228-34. doi: 10.1097/00002826-199106000-00005.
L-deprenyl (Eldepryl) added to Sinemet CR in the treatment regimens of seven patients with Parkinson's disease (PD) and therapeutic response fluctuations (RF) allowed a statistically significant reduction in total daily levodopa intake and an increase in the mean interdose interval. Trends were noted towards a reduction in the number of daily "off" periods and an increase in the portion of the waking day spent "on." Three patients suffered an increase in the intensity of their dyskinesias, and discontinued taking deprenyl. Four patients, all of whom reported improved functioning during "off" periods, have continued taking the combination. Sinemet CR and deprenyl can safely be used together in patients with advanced PD, and the combination may result in improved control of motor fluctuations in selected patients.
在七名帕金森病（PD）伴治疗反应波动（RF）患者的治疗方案中，添加左旋司来吉兰（安齐来）至息宁控释片，可使每日左旋多巴总摄入量在统计学上显著减少，并使平均给药间隔时间延长。有每日“关”期数量减少和清醒时“开”期时间占比增加的趋势。三名患者出现运动障碍强度增加，停止服用司来吉兰。四名患者均报告在“关”期功能改善，继续服用该联合用药。息宁控释片和司来吉兰可安全地用于晚期PD患者，该联合用药可能会改善部分患者的运动波动控制情况。
